Kiniksa Pharmaceuticals 8-K Filing on Shareholder Votes

Ticker: KNSA · Form: 8-K · Filed: 2025-06-03T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, filing

TL;DR

Kiniksa Pharma filed an 8-K for shareholder votes. All good.

AI Summary

Kiniksa Pharmaceuticals International, plc filed an 8-K on June 3, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate structure and its principal executive offices located at 23 Old Bond Street, Floor 3, London, England.

Why It Matters

This filing indicates that Kiniksa Pharmaceuticals International, plc is engaging in formal processes involving its shareholders, which could relate to corporate governance or strategic decisions.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding shareholder votes and does not appear to contain significant new financial or operational risks.

Key Players & Entities

Kiniksa Pharmaceuticals International, plc (company) — Registrant
June 3, 2025 (date) — Date of earliest event reported
23 Old Bond Street, Floor 3, London, England (location) — Address of principal executive offices

FAQ

What specific matters were submitted to a vote of Kiniksa Pharmaceuticals International, plc's security holders?

The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not specify the exact matters in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 3, 2025.

What is the principal executive office address for Kiniksa Pharmaceuticals International, plc?

The principal executive offices are located at 23 Old Bond Street, Floor 3, London, England, W1S 4PZ.

What is the SEC file number for Kiniksa Pharmaceuticals International, plc?

The SEC file number is 001-38492.

What is the former name of Kiniksa Pharmaceuticals International, plc?

The former company name was Kiniksa Pharmaceuticals, Ltd., with a date of name change on 20180205.

From the Filing

0001104659-25-055990.txt : 20250603 0001104659-25-055990.hdr.sgml : 20250603 20250603163039 ACCESSION NUMBER: 0001104659-25-055990 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250603 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250603 DATE AS OF CHANGE: 20250603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 251020091 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 8-K 1 tm2517053d1_8k.htm FORM 8-K false 0001730430 0001730430 2025-06-03 2025-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): June 3, 2025   Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter)   England and Wales   001-730430   98-1795578 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.)   23 Old Bond Street, Floor 3 London , W1S 4PZ England , United Kingdom (Address of principal executive offices, including zip code)   ( 781 ) 431-9100 (Registrant’s telephone number, including area code)   N/A (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Class A Ordinary Shares, $0.000273235 nominal value   KNSA   The Nasdaq Stock Market LLC         (Nasdaq Global Select Market)   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨           Item 5.07 Submission of Matters to a Vote of Security Holders.   On June 3, 2025, Kiniksa Pharmaceuticals International, plc (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) at which a quorum was present. Holders of the Company’s Class A ordinary shares (“Class A Shares”) an